Phase II Ergebnisse und News

Die unten stehende Meldung kam vor einigen Stunden raus. Man beachte, dass Genocea in Kürze Ergebnisse zu ihrer Phase II Studie (GEN-003) veröffentlichen wird.

Sphera Funds Management Ltd. buys $2,345,727 stake in Genocea Biosciences Inc (GNCA)

http://www.losangelesmirror.net/201603/24/...ciences-inc-gnca-340511/

LG, biotech  

https://seekingalpha.com/article/...-biosciences-really-pull-makeover  

https://m.nasdaq.com/de/symbol/gnca/real-time  

https://www.nasdaq.com/de/symbol/gnca/real-time  

 

unter 1 $ bleiben? dann gehts noch weiter runter...  

http://globenewswire.com/news-release/2018/08/29/...-Conferences.html  

https://www.nasdaq.com/de/symbol/gnca/real-time  

https://www.ariva.de/genocea_biosciences-aktie/...ek&boerse_id=40  

https://www.nasdaq.com/de/symbol/gnca/real-time  

• MK 49 Mio. $
  
• Q3/18 Cash ~34 Mio. $
  
• Q3/18 Verlust ~adj. 10 Mio. $
  

"Genocea expects that its existing cash and cash equivalents are sufficient to support its operating expenses and capital expenditure requirements into the fourth quarter of 2019.

Genocea continues to explore strategic alternatives for GEN-003, its Phase 3-ready investigational immunotherapy for the treatment of genital herpes."

https://ir.genocea.com/news-releases/...-2018-financial-and-operating

 

ansehlichem Volumen!  

https://www.streetinsider.com/Corporate+News//...rrants/15112633.html


Außer mir noch Jemand hier?  

https://www.nasdaq.com/de/symbol/gnca/real-time  

• MK ~60 Mio. $
  
• Loss from operations ~9 Mio. $
  
• Cash 26 Mio. $
  

"Genocea expects that its existing cash and cash equivalents are sufficient to support its operations into the first quarter of 2020.

Genocea continues to explore strategic alternatives for GEN-003, its Phase 3-ready investigational immunotherapy for the treatment of genital herpes.

Genocea’s Board of Directors has adopted a resolution approving and recommending that stockholders support a proposal in the company’s upcoming proxy statement to effect a reverse stock split of the company’s issued and outstanding common stock, if necessary, to maintain the company’s NASDAQ Capital Market listing."

https://ir.genocea.com/news-releases/...-results-and-announces-hiring

 

...auch wenn man hier echt einen langen Atem und Geduld braucht

https://www.analystratings.com/articles/...ces-is-exercising-options/  

http://www.globenewswire.com/news-release/2019/04/...-Inhibitors.html  

https://www.nasdaq.com/de/symbol/gnca/real-time  

Genocea meldet Zahlen für Q1/19

• keine Umsätze
  
• Verlust 16 Mio. $
  
• Cash 29 Mio. $
  
• MK 84 Mio. $
  

https://ir.genocea.com/news-releases/...-including-first-quarter-2019

 

• am 22. Mai gab es einen 8/1 Split
  
• Kurs nach dem Split ~4,75$
  
• Daten zu GEN-009
  

https://ir.genocea.com/news-releases/...emonstrates-best-class-immune

 

• würde mich nicht wundern, wenn hier bald ein Offering kommen würde
  

https://seekingalpha.com/news/...ve-genminus-009-data-cancer-patients

 

Tadaa, hier ist das Offering:

• 10,5 Mio. Aktien zu je 3,50 $ = rund 37 Mio. $
  

https://ir.genocea.com/news-releases/...-public-offering-common-stock

 

Genocea meldet Zahlen für Q2/19

• keine Umsätze
  
• op. Verlust 10 Mio. $
  
• Cash 59 Mio. $
  
• MK 83 Mio. $
  

https://ir.genocea.com/news-releases/...including-second-quarter-2019